Glucagon-like peptide-1 receptor agonist (GLP-1-RAS) treatment in patients with cirrhosis: A scoping review

  • Juan Sebastián Hernández Puentes Department of Internal Medicine, Faculty of Medicine, Universidad de La Sabana, Chía, Colombia
  • Carlos Andrés Granados Burgos Department of Internal Medicine, Faculty of Medicine, Universidad de La Sabana, Chía, Colombia
  • Natalia Sofia Jiménez Novoa Department of Internal Medicine, Faculty of Medicine, Universidad de La Sabana, Chía, Colombia
  • Athala Inés Larrarte González Department of Internal Medicine, Faculty of Medicine, Universidad de La Sabana, Chía, Colombia
  • María Fernanda Velasco Becerra Department of Internal Medicine, Faculty of Medicine, Universidad de La Sabana, Chía, Colombia
  • Laura Daniela Bilbao Rubiano Department of Internal Medicine, Faculty of Medicine, Universidad de La Sabana, Chía, Colombia
  • Valentina Puentes Caycedo Department of Internal Medicine, Faculty of Medicine, Universidad de La Sabana, Chía, Colombia
Keywords: cirrhosis, glucagon-like peptide-1 receptor agonists, diabetes

Abstract

Cirrhosis is a chronic disease characterized by diffuse fibrosis and morphological changes in the hepatic parenchyma. It is estimated that one-third of patients with cirrhosis also have diabetes. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown significant benefits in managing liver diseases, such as nonalcoholic fatty liver disease. However, little is known about its utility in patients with cirrhosis. This study aimed to explore the existing literature on the use of GLP-1 analogs in patients with hepatic cirrhosis, examining their potential advantages and disadvantages and possible indications for their use. Scoping reviews that included PubMed, Scopus, the International Clinical Trials Registry Platform search portal and ClinicalTrials were used. Six publications were included: prospective cohort (n=1), retrospective cohort (n=3), and clinical trial (n=2). The use of GLP-1 RAs proved beneficial in cirrhosis, demonstrating a decrease in mortality and complications and a reduction in weight. Using them over other available antidiabetic agents in this patient population is preferable. However, GLP-1 analogs in advanced fibrosis stages do not appear to be effective in reversing this condition.

Published
2024-12-16
How to Cite
Hernández Puentes, Juan, Carlos Granados Burgos, Natalia Jiménez Novoa, Athala Larrarte González, María Velasco Becerra, Laura Bilbao Rubiano, and Valentina Puentes Caycedo. 2024. “Glucagon-Like Peptide-1 Receptor Agonist (GLP-1-RAS) Treatment in Patients With Cirrhosis: A Scoping Review”. Romanian Journal of Diabetes Nutrition and Metabolic Diseases 31 (4), 466-73. http://rjdnmd.org/index.php/RJDNMD/article/view/1553.